[Use of improved RD114 envelope pseudotyped vectors capable of transducing >95% of CD34+ stem cells ex vivo, together with non-ablative marrow conditioning will be incorporated into the next generation of clinical trials of ex vivo gene therapy for CGD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
Gene-disease associations inferred from text-mining the literature.
DisGeNET evidence - LITERATURE